文献类型：期刊文献

英文题名：Comparative analysis of hysterectomy types and approaches on oncological survival in 2023 FIGO stage II endometrial carcinoma

作者：Sun, Jianhao[1,2,3];Wu, Zhenzhen[3,4];Chen, Jiayu[4];Hang, Qinglei[5];Zhao, Yaqin[3,4];Li, Juan[3];Huang, Jie[3];Zhao, Xiaoli[4];Xia, Ji[1,2];Jiao, Xinjuan[3,4];Liu, Qing[3,4];Lu, Dan[1,2]

第一作者：Sun, Jianhao

通信作者：Lu, D[1];Lu, D[2];Liu, Q[3];Liu, Q[4]

机构：[1]Yangzhou Univ, Northern Jiangsu Peoples Hosp, Yangzhou 225001, Peoples R China;[2]Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou 225001, Peoples R China;[3]Gansu Prov Matern & Child Care Hosp, Lanzhou 730000, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China;[5]Yangzhou Univ, Key Lab Jiangsu Prov Univ Nucl Acid & Cell Fate Ma, Med Coll, Dept Clin Med, Yangzhou 225001, Peoples R China

第一机构：Yangzhou Univ, Northern Jiangsu Peoples Hosp, Yangzhou 225001, Peoples R China

通信机构：[1]corresponding author), Yangzhou Univ, Northern Jiangsu Peoples Hosp, Yangzhou 225001, Peoples R China;[2]corresponding author), Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou 225001, Peoples R China;[3]corresponding author), Gansu Prov Matern & Child Care Hosp, Lanzhou 730000, Gansu, Peoples R China;[4]corresponding author), Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China.|[10735]甘肃中医药大学;

年份：2025

卷号：25

期号：1

外文期刊名：BMC SURGERY

收录：;Scopus(收录号：2-s2.0-105005095180);WOS:【SCI-EXPANDED(收录号:WOS:001488515400001)】；

基金：This research was partially funded by the National Natural Science Foundation of China (No. 82072088), the Natural Science Foundation of Gansu Province (No. 22JR5RA718 and 24JRRA621), and the Postgraduate Research & Practice Innovation Program of Jiangsu Province.

语种：英文

外文关键词：Stage II; FIGO; Hysterectomy; Disease-free survival; Endometrial carcinoma

摘要：BackgroundThe objective is to investigate the relationship between the type and approaches of hysterectomy and the oncological survival outcomes in women diagnosed with stage II endometrial carcinoma (EC), as classified by the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system.MethodsA retrospective analysis was conducted on patients with 2009 FIGO early-stage (stages I and II) EC who underwent surgical treatment between 2018 and 2019. These patients were reclassified in accordance with the 2023 FIGO staging system, and those diagnosed with stage II EC under this system were selected as the study population. A non-inferiority test was employed for the analysis, with disease-free survival (DFS) serving as the primary outcome measure. DFS was evaluated using Kaplan-Meier curves, and comparisons were conducted through the log-rank test.ResultA cohort of 288 patients diagnosed with early-stage EC according to the 2009 FIGO staging system were re-evaluated and reclassified. Ultimately, the study encompassed a cohort of 80 patients diagnosed with stage II EC, as classified according to the 2023 FIGO staging system. 52 individuals underwent radical hysterectomy or modified radical hysterectomy (RH/mRH), while 28 patients received a simple hysterectomy (SH). The 5-year DFS was 84.62% for the RH/mRH group vs. 92.86% for the SH group (difference, 8.24% [95% CI, -5.44-21.92%]), which met the noninferiority criterion. Between the groups, the difference in 5-year DFS (p = 0.255) was not statistically significant. The laparoscope group comprised 62 cases, whereas the laparotomy group consisted of 18 cases. Between the groups, the difference in 5-year DFS (88.55% versus 83.33%, p = 0.538) was not statistically significant. This finding aligns with our observations of patients diagnosed with 2009 FIGO Stage II EC.ConclusionIn comparison to SH, RH/mRH did not confer a survival advantage for patients diagnosed with 2023 FIGO stage II EC.